Archemix to Present at the 28th Annual Canaccord Adams Global Growth Conference.CAMBRIDGE Cambridge, city, Canada Cambridge (kām`brĭj), city (1991 pop. 92,772), S Ont., Canada, on the Grand River, NW of Hamilton. It was formed in 1973 with the amalgamation of Galt, Hespeler, and Preston, all founded in the early 19th cent. , Mass. -- Archemix Corp, a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. , today announced that Dr. Errol De Souza De Souza or D'Souza is a common Portuguese family name. Although it is still quite common outside Portugal -- especially in Brazil and India --, Souza is the old spelling of present-day Sousa. , Archemix's President and Chief Executive Officer, will present at the 28th Annual Canaccord Adams Global Growth Conference in Boston on Wednesday, August 13th at 11:30 a.m. In his presentation Dr. De Souza will provide an update on Archemix's product portfolio, including the company's ARC1779 aptamer, and strategic and business initiatives and goals for 2008. About Aptamers Aptamers are synthetically-derived oligonucleotides, or short nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. sequences, that bind to protein targets with high affinity and specificity and can be designed to have a specified duration of action. Aptamers represent an emerging class of potential therapeutic agents that Archemix believes may have broad application to treat a variety of human diseases. About Archemix Archemix is a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics. Using Archemix's proprietary processes for discovering aptamers, which are protected by its broad patent portfolio, Archemix is developing aptamer product candidates for rare hematological hematological, hematologic pertaining to or emanating from blood cells. hematological tests total and differential white cell counts, hematocrit estimation, erythrocyte count. diseases. In addition, Archemix has licensed its intellectual property to third parties to develop their own aptamer product candidates. Currently, Archemix and its licensees are evaluating four different aptamer product candidates in human clinical trials; two in Phase 2 and two in Phase 1. To date, Archemix has licensed its intellectual property to discover and develop aptamer product candidates to nine biotechnology and pharmaceutical companies, including Pfizer, Merck Serono In September 2006, Merck KGaA announced its intent to purchase the majority of Serono shares from Ernesto Bertarelli and the Bertarelli family. The Merck-Serono merger was announced on September 21, 2006. Merck KGaA and Serono operated as distinct entities until at least January 2007. and Takeda Pharmaceuticals. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion